Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,110.3
-17.4 (-0.56%)

 

  • STI Straits Times Index
    3,110.3
    -17.4 (-0.56%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,609.3
    6.9 (0.43%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,179.3
    130.6 (0.50%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,897.4
    14.0 (0.49%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    20,710.9
    82.9 (0.40%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,255.6
    16.4 (0.26%)
    Index delayed 10 minutes
  • KOR KOSPI
    1,948.3
    -2.7 (-0.14%)
    Index delayed 20 minutes
  • XAO XAO
    6,614.3
    21.3 (0.32%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 728.4M
  • Value: 924.6M
  • Rise: 102
  • Fall: 203
  • Unch: 530

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
LionGold0.001-
Rex Intl0.083+0.007
YZJ Shipbldg SGD0.915-0.015
ThaiBev0.935+0.005
Mapletree NAC Tr1.310-0.030
SingTel3.250+0.010
TEE Intl0.062-0.004
CapitaMall Trust2.640+0.020
HPH Trust USD0.167-0.010
SPH2.040-0.090

World Indices

World Indices
Name Last Change
Nasdaq 7,991.4 -28.8
HSI 26,179.3 +130.6
HSCEI 10,194.7 +71.8
Jakarta 6,255.6 +16.4
Nikkei 225 20,710.9 +82.9
SSE Comp 2,897.4 +14.0
Shanghai A 3,035.4 +14.7
Shanghai B 264.6 +0.3
PSE Comp 0.0
KOSPI 1,948.3 -2.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

RHYTHM PHARMACEUTICALS INC RHYTHM PHARMACEUTICALS
Updated on 22 Aug 2019 (End of trading day)
Last (USD): 21.550 Change: -0.150 High: 21.840 Remarks: -
Change (%): -0.69 Low: 21.320
Open 21.780 Yesterday's Close 21.7
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 117,017 Cumulative Value
 
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -2.14585 Trailing EPS (USD) e -3.33081 NAV (USD) b 5.2576
PE a - Trailing PE f - Price / NAV b 4.0988
Dividend (USD) d - Cash In Hand (USD) g 1.8287 Issued & Paid-up Shares c 34,515,000
Dividend Yield (%) d - Price / Cash In Hand g 11.784 Treasury Shares h -
Beta - 75 Daysi 0.235 R-Squared - 75 Days(%)i 0.63 Market Cap (M) 743.798
Beta - 500 Daysi 0.094 R-Squared - 500 Days (%)i 0.07 Enterprise Value (M) 552.341
Piotroski F Score 1 Exchange Code RYTM Par Value ( $ ) n.a.
52 Weeks Volatility (%) 41.26 Free Float (%) 61.3
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 31 Jul 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 05 Oct 2017.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference RHYTHM PHARMACEUTICALS INC NASDAQ 743.798 - - 4.0988 -
Industry Biotechnology NASDAQ 2,237.551 127.732 99.033 5.1707 0.790
Local Peer AMGEN INC NASDAQ 121,991.177 14.533 15.329 11.3017 2.725
Local Peer GILEAD SCIENCES INC NASDAQ 81,331.419 14.910 13.658 3.5962 3.594
Local Peer CELGENE CORP NASDAQ 67,833.601 16.766 12.869 6.7489 -
Local Peer VERTEX PHARMACEUTICAL NASDAQ 47,356.128 22.589 21.380 9.3405 -
Local Peer BIOGEN INC NASDAQ 42,802.771 9.661 8.085 3.3045 -
Local Peer ILLUMINA INC NASDAQ 42,421.260 51.357 45.225 9.7925 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,421.031 13.263 15.668 3.3232 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,689.792 356.825 20.763 2.7244 -
Local Peer INCYTE CORPORATION NASDAQ 18,401.133 168.058 60.160 8.1885 -
Local Peer EXACT SCIENCES CORP NASDAQ 15,262.397 - - 19.9371 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 13,890.436 - - 4.6912 -
Local Peer SEATTLE GENETICS INC NASDAQ 13,232.105 - - 10.4040 -
Other Local Peers IONIS PHARMACEUTICALS INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BIO-TECHNE CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), EXELIXIS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), REPLIGEN CORP (NASDAQ), MODERNA INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), FIBROGEN INC (NASDAQ), ALKERMES PLC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), TILRAY INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), NATERA INC (NASDAQ), UNIQURE N.V. (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), VERACYTE INC (NASDAQ), EPIZYME INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), OPKO HEALTH INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), OMEROS CORP (NASDAQ), INTREXON CORP (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), CYTOKINETICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), MACROGENICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), NEXTCURE INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CORTEXYME INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), PERSONALIS INC (NASDAQ), AVROBIO INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), SINOVAC BIOTECH (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), AGENUS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), RESTORBIO INC (NASDAQ), MEDICINOVA INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), XBIOTECH INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), PDL BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), RECRO PHARMA INC (NASDAQ), GERON CORP (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), CHIASMA INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), ARDELYX INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), MANNKIND CORPORATION (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ATHERSYS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), AFFIMED N V (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), NOVAVAX INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), GLYCOMIMETICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), IMV INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), NANTKWEST INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), TOCAGEN INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), VERASTEM INC (NASDAQ), SYNLOGIC INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), SAVARA INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), VACCINEX INC (NASDAQ), TREVENA INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), ORGENESIS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), OTONOMY INC (NASDAQ), EQUILLIUM INC (NASDAQ), CURIS INC (NASDAQ), ARAVIVE INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), COHBAR INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), INMUNE BIO INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), VERMILLION INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), IVERIC BIO INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), EVOGENE LTD (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), ZAFGEN INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), SENESTECH INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), BIOCEPT INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), SOLIGENIX INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), HISTOGENICS CORP (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), VICAL INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), PRECIPIO INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), TROVAGENE INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), VAXART INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ADVAXIS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), OPGEN INC (NASDAQ), NEURALSTEM INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ)
Global Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Global Peer CSL ASX 108,005.681 40.257 40.257 14.4332 1.124
Global Peer AGILENT TECHNOLOGIES INC NYSE 22,669.338 71.739 21.147 4.7755 0.836
Global Peer SINO BIOPHARM HKEx 135,076.224 12.606 12.940 3.8969 0.681
Global Peer WUXI BIO HKEx 105,284.288 140.960 110.199 10.8378 -
Global Peer BEIGENE HKEx 68,714.455 - - 5.6603 -
Global Peer Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Global Peer GENSCRIPT BIO HKEx 33,218.258 199.776 199.771 8.8637 -
Global Peer 3SBIO HKEx 31,632.750 20.911 36.298 - -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,146.560 34.235 - 2.1707 -
Other Global Peers FRONTAGE (HKEx), VIVA BIOTECH (HKEx), POLYNOVO LIMITED (ASX), HAOHAI BIOTEC (HKEx), MYOVANT SCIENCES LTD (NYSE), ASCLETIS-B (HKEx), AVITA MEDICAL LTD (ASX), MESOBLAST LTD (ASX), CKLIFE SCIENCES (HKEx), ESSEX BIO-TECH (HKEx), NEXT SCIENCE LTD (ASX), KADMON HLDGS INC (NYSE), STARPHARMA HOLDINGS LIMITED (ASX), ARCUS BIOSCIENCES INC (NYSE), LEE'S PHARM (HKEx), TELIX PHARMACEUTIC (ASX), DPHARMA (Bursa), 22ND CENTURY GROUP INC (NYSE American), PFENEX INC (NYSE American), ENZO BIOCHEM INC (NYSE), LINEAGE CELL THERAPEUTICS INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), STANDARD DIVERSIFIED INC (NYSE American), UNI-BIO GROUP (HKEx), BBI LIFE SCI (HKEx), CYNATA THERAPEUTICS LTD (ASX), NEUREN PHARMACEUTICALS LTD (ASX), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), PORT (SET), CEL-SCI CORP (NYSE American), IBIO INC (NYSE American), RESAPP HEALTH LIMITED (ASX), PHYLOGICA LIMITED (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), IMMUTEP LTD (ASX), HEMISPHERX BIOPHARMA INC (NYSE American), IMUGENE LIMITED (ASX), CT ENTERPRISE (HKEx), SYNTHETIC BIOLOGICS INC (NYSE American), REGENT PACIFIC (HKEx), ARMATA PHARMACEUTICALS INC (NYSE American), ORTHOCELL LIMITED (ASX), ZELDA THERAPEUTICS LTD (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), BIOTRON (ASX), RHINOMED LIMITED (ASX), ONCOSIL MEDICAL LIMITED (ASX), INVEX THERAPEUTICS LTD NPV (ASX), EXTRAWELL PHAR (HKEx), BIOSINO BIO-TEC (HKEx), ORAGENICS INC (NYSE American), MEMPHASYS LTD (ASX), ISORAY INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), KAZIA THERAPEUTICS LIMITED (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), REGENEUS LTD (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), BIONOMICS LTD (ASX), ADALTA LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), NANOVIRICIDES INC (NYSE American), Suntar Eco-City^ (SGX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), CELLMID LIMITED (ASX), IMMURON LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), BIOXYNE LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), LIVING CELL TECHNOLOGIES (ASX), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD (ASX), ANATARA LIFESCIENCES LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ACTINOGEN MEDICAL LTD (ASX), MGRC (Bursa), MEGASUN (Bursa), CCP TECHNOLOGIES LTD (ASX), QT Vascular (SGX), TBG DIAGNOSTICS LTD (ASX), NANOLLOSE LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), BPH ENERGY LIMITED (ASX), NOVITA HEALTHCARE LTD (ASX), MEDIBIO LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), ALCHEMIA LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.950
+4.61 %
10 Days -+0.220
+1.03 %
20 Days -+1.560
+7.80 %
Medium Term Return 3 Months --4.450
-17.12 %
6 Months --5.970
-21.69 %
1 Year --10.120
-31.95 %
Annualised Return Annualised --
-31.95 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 18.000 - 34.630 Change From 1 Year Low +3.550 % Change From 1 Year Low (%) +19.72
Change From 1 Year High -13.080 % Change From 1 Year High (%) -37.77
2 Years Range 16.800 - 37.230 Change From 2 Years Low +4.750 % Change From 2 Years Low (%) +28.27
Change From 2 Years High -15.680 % Change From 2 Years High (%) -42.12
5 Years Range 16.800 - 37.230 Change From 5 Years Low +4.750 % Change From 5 Years Low (%) +28.27
Change From 5 Years High -15.680 % Change From 5 Years High (%) -42.12
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.

Historical Price Data

Date Open High Low Close Volume VWAP
22 Aug 2019 21.780 21.840 21.320 21.550 117,017 -
21 Aug 2019 21.370 21.820 21.190 21.700 92,396 -
20 Aug 2019 21.280 21.650 21.150 21.480 125,328 -
19 Aug 2019 20.800 21.290 20.364 21.100 130,683 -
16 Aug 2019 20.190 20.650 20.020 20.600 150,773 -
15 Aug 2019 19.910 20.610 19.410 19.880 145,776 -
14 Aug 2019 19.520 20.170 18.840 20.000 253,228 -
13 Aug 2019 18.780 19.950 18.552 19.940 162,056 -
12 Aug 2019 21.410 21.410 18.650 18.810 347,687 -
09 Aug 2019 21.870 22.170 21.160 21.330 210,707 -
08 Aug 2019 21.970 22.626 21.860 22.030 315,742 -
07 Aug 2019 24.370 24.500 20.950 21.840 2,975,079 -
06 Aug 2019 19.080 19.340 18.630 19.000 175,447 -
05 Aug 2019 19.070 19.595 18.530 18.620 192,513 -
02 Aug 2019 19.270 19.540 19.045 19.420 320,899 -
01 Aug 2019 19.250 19.920 18.920 19.250 430,866 -
31 Jul 2019 19.030 20.060 19.030 19.250 332,988 -
30 Jul 2019 18.000 19.780 18.000 19.050 328,579 -
29 Jul 2019 20.090 20.350 19.520 19.890 160,399 -
26 Jul 2019 20.080 20.270 19.750 19.990 129,017 -
25 Jul 2019 20.730 20.730 19.670 20.040 138,195 -
24 Jul 2019 20.490 20.970 20.270 20.720 97,663 -
Summary
Current 2 Weeks
(09 Aug 2019 to 22 Aug 2019)		 21.870 22.170 18.552 21.550 1,735,651 -
Previous 2 Weeks
(26 Jul 2019 to 08 Aug 2019)		 20.080 22.170 18.552 22.030 5,361,529 -
4 Weeks from
(27 Jun 2019 to 25 Jul 2019)		 21.550 22.170 18.552 20.040 4,794,594 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.